Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 1116-1123

  Adjei, Alex A ^a   Klein, Cheri E ^a   Kastrissios, Helen ^a   Goldberg, Richard M ^a   Alberts, Steven R ^a   Pitot, Henry C ^a   Sloan, Jeff A ^a   Reid, Joel M ^a   Hanson, Lorelei J ^a   Atherton, Pamela ^a   Rubin, Joseph ^a   Erlichman, Charles ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; FEMALE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS;

EID: 0034001776     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.1116     Document Type: Article

References (24)

1. Bissery MC, Nohynek G, Sanderink GJ, et al: Docetaxel: A review of preclinical and clinical experience - Part I. Preclinical experience. Anticancer Drugs 6:339-368, 1995
2. Riou JF, Naudin A, Lavelle F: Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164-170, 1992
3. van Oosterom AT, Schrilivers D: Docetaxel: A review of preclinical and clinical experience - Part II. Clinical experience. Anticancer Drugs 6:356-368, 1995
4. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of Taxotere, a taxol analogue. Cancer Res 51:4845-4852, 1991
5. Boven E, Venema-Gaberscek E, Erkelens CAM, et al: Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. Ann Oncol 4:321-324, 1993
6. Fulton B, Spencer CM: Docetaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 51:1075-1092, 1996
7. Crommentuyn KM, Schellens JH, van den Berg JD, et al: In-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev 24:345-366, 1998
8. Rivory LP, Bowles MR, Robert J, et al: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111, 1996
9. Pommier Y: Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecins. Semin Oncol 23:3-10, 1996 (Suppl 3)
10. Fassberg J, Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684, 1992
11. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
12. Rothenberg ML: CPT-11: An original spectrum of clinical activity. Semin Oncol 23:21-26, 1996 (Suppl 3)
13. Chou T-C, Motzer R, Tong Y, et al: Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
14. Kaufmann SH, Peereboom D, Buckwalter CA, et al: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741, 1996
15. Pitot HC, Erlichman C, Goldberg RM, et al: Phase I trial of irinotecan (CPT-11) given once every three weeks to patients with advanced solid tumors. Proc Am Soc Clin Oncol 15:494, 1996 (abstr 1581)
16. Abigerges D, Armand J-P, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
17. Bruno R, Vivier N, Vergniol JC, et al: A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. J Pharmacokin Biopharm 24:153-172 1996
18. Vergniol JC, Bruno R, Montay G, et al: Determination of taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278, 1992
19. Beal SL, Sheiner LB (eds): NONMEM Users Guides. San Francisco, CA, NONMEM Project Group, University of California at San Francisco, 1992
20. Efron B., Tibsharini R: An Introduction to the Bootstrap. New York, NY, Chapman and Hall, 1993
21. Couteau C, Lokiec F, Vermillet L, et al: Phase I dose-finding and pharmacokinetic study of docetaxel in combination with irinotecan in advanced solid tumors. Proc Am Soc Clin Oncol 16:202a, 1997 (abstr 709)
22. Marre F, Sanderink GJ, de Sousa G, et al: Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302, 1996
23. Choudhuri S, Zhang XJ, Waskiewicz MJ, et al: Differential regulation of cytochrome P450 3A1 and P450 3A2 in rat liver following dexamethasone treatment. J Biochem Toxicol 10:299-307, 1995
24. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker Inc, 1982.